M

Monte Rosa Therapeutics Inc
NASDAQ:GLUE

Watchlist Manager
Monte Rosa Therapeutics Inc
NASDAQ:GLUE
Watchlist
Price: 5.49 USD -3.17% Market Closed
Market Cap: 337.3m USD
Have any thoughts about
Monte Rosa Therapeutics Inc?
Write Note

Intrinsic Value

GLUE's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one GLUE stock under the Base Case scenario is 1.83 USD. Compared to the current market price of 5.49 USD, Monte Rosa Therapeutics Inc is Overvalued by 67%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

GLUE Intrinsic Value
1.83 USD
Overvaluation 67%
Intrinsic Value
Price
M
Worst Case
Base Case
Best Case

Valuation History
Monte Rosa Therapeutics Inc

Intrinsic Value History
Dive into the past to invest in the future

Uncover deeper insights with the Valuation History. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start now and learn if your stock is truly undervalued or overvalued!

Start Valuation
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
GLUE
Valuation History
HIDDEN
Show
Valuation History Unavailable

Historical valuation for GLUE cannot be conducted due to limitations such as insufficient data or other constraints.

Valuation In Progress...
Valuation In Progress...

Fundamental Analysis

Monte Rosa Therapeutics Inc
NASDAQ:GLUE
US
Biotechnology
Market Cap
337m USD
IPO
Jun 24, 2021
US
Biotechnology
Market Cap
337m USD
IPO
Jun 24, 2021
Price
$
$
Company Overview
Loading...
Economic Moat
Loading...
Management
Loading...
Contacts
Loading...
How do you feel about GLUE?
Bearish
Neutral
Bullish
AI Assistant
AI Assistant
Ask me anything about Monte Rosa Therapeutics Inc

Provide an overview of the primary business activities
of Monte Rosa Therapeutics Inc.

What unique competitive advantages
does Monte Rosa Therapeutics Inc hold over its rivals?

What risks and challenges
does Monte Rosa Therapeutics Inc face in the near future?

Has there been any significant insider trading activity
in Monte Rosa Therapeutics Inc recently?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Monte Rosa Therapeutics Inc.

Provide P/S
for Monte Rosa Therapeutics Inc.

Provide P/E
for Monte Rosa Therapeutics Inc.

Provide P/OCF
for Monte Rosa Therapeutics Inc.

Provide P/FCFE
for Monte Rosa Therapeutics Inc.

Provide P/B
for Monte Rosa Therapeutics Inc.

Provide EV/S
for Monte Rosa Therapeutics Inc.

Provide EV/GP
for Monte Rosa Therapeutics Inc.

Provide EV/EBITDA
for Monte Rosa Therapeutics Inc.

Provide EV/EBIT
for Monte Rosa Therapeutics Inc.

Provide EV/OCF
for Monte Rosa Therapeutics Inc.

Provide EV/FCFF
for Monte Rosa Therapeutics Inc.

Provide EV/IC
for Monte Rosa Therapeutics Inc.

Show me price targets
for Monte Rosa Therapeutics Inc made by professional analysts.

What are the Revenue projections
for Monte Rosa Therapeutics Inc?

How accurate were the past Revenue estimates
for Monte Rosa Therapeutics Inc?

What are the Net Income projections
for Monte Rosa Therapeutics Inc?

How accurate were the past Net Income estimates
for Monte Rosa Therapeutics Inc?

What are the EPS projections
for Monte Rosa Therapeutics Inc?

How accurate were the past EPS estimates
for Monte Rosa Therapeutics Inc?

What are the EBIT projections
for Monte Rosa Therapeutics Inc?

How accurate were the past EBIT estimates
for Monte Rosa Therapeutics Inc?

Compare the revenue forecasts
for Monte Rosa Therapeutics Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Monte Rosa Therapeutics Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Monte Rosa Therapeutics Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Monte Rosa Therapeutics Inc compared to its peers.

Compare the P/E ratios
of Monte Rosa Therapeutics Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Monte Rosa Therapeutics Inc with its peers.

Analyze the financial leverage
of Monte Rosa Therapeutics Inc compared to its main competitors.

Show all profitability ratios
for Monte Rosa Therapeutics Inc.

Provide ROE
for Monte Rosa Therapeutics Inc.

Provide ROA
for Monte Rosa Therapeutics Inc.

Provide ROIC
for Monte Rosa Therapeutics Inc.

Provide ROCE
for Monte Rosa Therapeutics Inc.

Provide Gross Margin
for Monte Rosa Therapeutics Inc.

Provide Operating Margin
for Monte Rosa Therapeutics Inc.

Provide Net Margin
for Monte Rosa Therapeutics Inc.

Provide FCF Margin
for Monte Rosa Therapeutics Inc.

Show all solvency ratios
for Monte Rosa Therapeutics Inc.

Provide D/E Ratio
for Monte Rosa Therapeutics Inc.

Provide D/A Ratio
for Monte Rosa Therapeutics Inc.

Provide Interest Coverage Ratio
for Monte Rosa Therapeutics Inc.

Provide Altman Z-Score Ratio
for Monte Rosa Therapeutics Inc.

Provide Quick Ratio
for Monte Rosa Therapeutics Inc.

Provide Current Ratio
for Monte Rosa Therapeutics Inc.

Provide Cash Ratio
for Monte Rosa Therapeutics Inc.

What is the historical Revenue growth
over the last 5 years for Monte Rosa Therapeutics Inc?

What is the historical Net Income growth
over the last 5 years for Monte Rosa Therapeutics Inc?

What is the current Free Cash Flow
of Monte Rosa Therapeutics Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Monte Rosa Therapeutics Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Monte Rosa Therapeutics Inc

Current Assets 251.2m
Cash & Short-Term Investments 242.2m
Receivables 595k
Other Current Assets 8.4m
Non-Current Assets 63.9m
PP&E 58.8m
Other Non-Current Assets 5.1m
Current Liabilities 41.6m
Accounts Payable 4m
Accrued Liabilities 18.7m
Other Current Liabilities 18.9m
Non-Current Liabilities 68m
Other Non-Current Liabilities 68m
Efficiency

Free Cash Flow Analysis
Monte Rosa Therapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Monte Rosa Therapeutics Inc

Revenue
15m USD
Operating Expenses
-144m USD
Operating Income
-129m USD
Other Expenses
9.6m USD
Net Income
-119.4m USD
Fundamental Scores

GLUE Profitability Score
Profitability Due Diligence

Monte Rosa Therapeutics Inc's profitability score is 19/100. The higher the profitability score, the more profitable the company is.

19/100
Profitability
Score

Monte Rosa Therapeutics Inc's profitability score is 19/100. The higher the profitability score, the more profitable the company is.

GLUE Solvency Score
Solvency Due Diligence

Monte Rosa Therapeutics Inc's solvency score is 58/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Low D/E
Long-Term Solvency
Low Altman Z-Score
58/100
Solvency
Score

Monte Rosa Therapeutics Inc's solvency score is 58/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

GLUE Price Targets Summary
Monte Rosa Therapeutics Inc

Wall Street analysts forecast GLUE stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for GLUE is 16.7 USD with a low forecast of 11.11 USD and a high forecast of 21 USD.

Lowest
Price Target
11.11 USD
102% Upside
Average
Price Target
16.7 USD
204% Upside
Highest
Price Target
21 USD
283% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

Monte Rosa Therapeutics Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for GLUE is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

GLUE Insider Trading
Buy and sell transactions by insiders

What is the Intrinsic Value of one GLUE stock?

The intrinsic value of one GLUE stock under the Base Case scenario is 1.83 USD.

Is GLUE stock undervalued or overvalued?

Compared to the current market price of 5.49 USD, Monte Rosa Therapeutics Inc is Overvalued by 67%.

Back to Top